Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
Combined platform with 55+ centres aims to expand integrated maternity, fertility, neonatal and paediatric care across India
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Collaboration with Siddhi Diagnostics combines genomics and advanced imaging capabilities to strengthen precision diagnostics in high-growth suburban markets
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
